CYTR - CytRx Corporation
| Previous Close | 0.4312 |
| Open | 0.4350 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.3870 - 0.4350 |
| 52 Week Range | 0.2100 - 0.8500 |
| Volume | 38,656 |
| Avg. Volume | 308,212 |
| Market Cap | 13.27M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2190 |
| Earnings Date | Nov 08, 2018 - Nov 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- PR Newswire
CytRx Corporation Provides Update on Management Change
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today announced that effective immediately, Mr. Eric Curtis, President and Chief Operating Officer of CytRx Corporation and President and CEO of Centurion BioPharma Corporation, is stepping down to pursue another opportunity. Both roles at the appropriate time will be reviewed with the Board of Directors and decisions will be made regarding a replacement.
- PR Newswire
CytRx Corporation Clarifies Certain Prior Disclosures Regarding its Relationship with Orphazyme A/S
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A/S. As previously reported, in 2011 CytRx agreed to sell and transfer certain data, intellectual property rights and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Orphazyme A/S, which sale included conditional future payments to CytRx contingent upon the achievement of specified clinical/regulatory and sales milestones as well as single and double digit royalty payments, depending on the indication.
- PR Newswire
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted Orphazyme's recently published data from its double-blinded Phase 2 trial of arimoclomol for the treatment of Sporadic Inclusion Body Myositis (sIBM). This was a 24-patient randomized pilot trial (16 patients on arimoclomol and 8 on placebo) where 83% of arimoclomol treated patients were stabilized versus 25% on placebo. Four months of continuous treatment resulted in a 60% reduction in progression, and at 8 months (4 months after treatment discontinuation), there was a 75% reduction in progression.
- PR Newswire
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided updated clinical and regulatory guidance on arimoclomol milestones through 2021 in its four indications, amyotrophic lateral sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM), Niemann-Pick disease Type C (NPC) and Gaucher Disease. Pre-clinical work has also commenced in Parkinson's Disease.
- PR Newswire
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted that ImmunityBio, previously NantCell, Inc., and NantKwest announced a complete response in Metastatic Pancreatic Cancer in one patient who received its experimental Human Killer Cell combination Immunotherapy, which includes aldoxorubicin, in its Phase 1 clinical trial. This result builds on the results released previously in patients with Triple Negative Breast Cancer ("TNBC"), in which two of nine patients treated with this experimental cancer therapy also had a complete response. These immunotherapies include CytRx's aldoxorubicin as part of its innovative chemoradiation therapy. NantKwest also indicated they plan to initiate registration trials in recurrent metastatic TNBC and pancreatic cancer patients that failed standard of care.
- PR Newswire
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted Orphazyme A/S received FDA Breakthrough Therapy Designation for arimoclomol for NPC. Breakthrough Therapy Designation is a program intended to expedite the development and review of drugs to treat serious or life-threatening diseases in cases where preliminary clinical evidence shows that the drug may provide substantial improvements over available therapy.
- PR Newswire
CytRx Corporation Reports Second Quarter 2019 Financial Results
Licensee Orphazyme A/S Rapidly Completes Enrollment in Clinical Trials for Multiple Indications and Prepares for Regulatory Submissions LOS ANGELES , Aug. 9, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: ...
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
LOS ANGELES, July 30, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food and Drug Administration (FDA), arimoclomol licensee Orphazyme A/S (ORPH.CO) remains on track to submit a New Drug Application (NDA) for arimoclomol in Niemann-Pick Disease Type C (NPC) in the first half of 2020. Orphazyme also announced plans to introduce an Early Access Program for NPC in the fall of 2019.
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
LOS ANGELES, July 22, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evaluating arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) ahead of schedule. The Phase 3 trial of arimoclomol for ALS is a 76-week, randomized, placebo-controlled trial being conducted at 30 centers of excellence in North America and Europe.
- ACCESSWIRE
CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
LOS ANGELES, CA / ACCESSWIRE / June 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Eric L. Curtis, President and COO of CytRx Corporation ...
- PR Newswire
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room Temperature and Eliminates the Need for Cold Handling LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation ...
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
LOS ANGELES, June 19, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC). Based on advice received from the EMA's Scientific Advice Working Group, Orphazyme expects to submit the arimoclomol MAA in the first half of 2020.
- PR Newswire
CytRx Corporation to Commence Trading on OTCQB Venture Market
LOS ANGELES, May 31, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019, under the same ticker symbol "CYTR". Investors can find current financial disclosure and real-time Level 2 quotes for the Company on www.otcmarkets.com/stock/CYTR/quote.
- Associated Press
CytRx: 1Q Earnings Snapshot
The Los Angeles-based company said it had a loss of 4 cents per share. Losses, adjusted to account for discontinued operations, were 5 cents per share. The company's shares closed at 52 cents. A year ago, ...
- PR Newswire
CytRx Corporation Reports First Quarter 2019 Financial Results
Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing ...
- PR Newswire
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
- PR Newswire
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical ...
- PR Newswire
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a ...
- PR Newswire
CytRx Corporation Reports 2018 Financial Results
LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy Out-licensed Assets Aldoxorubicin and Arimoclomol with Strategic ...
- GlobeNewswire
Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
- Zacks
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- Associated Press
CytRx: 3Q Earnings Snapshot
On a per-share basis, the Los Angeles-based company said it had a loss of 10 cents. The cancer drug developer posted revenue of $250,000 in the period. The company's shares closed at 75 cents. A year ago, ...
- ACCESSWIRE
CytRx Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 11:00 AM Eastern Time. ...
- Associated Press
CytRx: 2Q Earnings Snapshot
The Los Angeles-based company said it had a loss of 10 cents per share. The company's shares closed at $1.15. A year ago, they were trading at $3.78. _____ This story was generated by Automated Insights ...
